



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lsyc20>

SYNTHESIS OF CYCLOPENTENE-FUSED PYRROLOISOQUINOLINONE DERIVATIVE VIA N-ACYLIMINIUM ION CYCLIZATION

Dong Jin Hwang^a, Soo Sung Kang^a, Jae Yeol Lee^a, Jung Hoon Choi^b, Hokoon Park^a & Yong Sup Lee^c

^a Division of Life Sciences, Korea Institute of Science and Technology, P.O. Box 131, Cheongryang, Seoul, 130-650, Korea

^b Department of Chemistry, Hanyang University, Seoul, 133-791, Korea

^c Division of Life Sciences, Korea Institute of Science and Technology, P.O. Box 131, Cheongryang, Seoul, 130-650, Korea

Published online: 16 Aug 2006.

To cite this article: Dong Jin Hwang, Soo Sung Kang, Jae Yeol Lee, Jung Hoon Choi, Hokoon Park & Yong Sup Lee (2002) SYNTHESIS OF CYCLOPENTENE-FUSED PYRROLOISOQUINOLINONE DERIVATIVE VIA N-ACYLIMINIUM ION CYCLIZATION, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 32:16, 2499-2505, DOI: [10.1081/SCC-120003411](https://doi.org/10.1081/SCC-120003411)

To link to this article: <http://dx.doi.org/10.1081/SCC-120003411>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>



SYNTHETIC COMMUNICATIONS

Vol. 32, No. 16, pp. 2499–2505, 2002

SYNTHESIS OF CYCLOPENTENE-FUSED PYRROLOISOQUINOLINONE DERIVATIVE VIA *N*-ACYLIMINIUM ION CYCLIZATION

Dong Jin Hwang,^{1,2} Soo Sung Kang,^{1,2} Jae Yeol Lee,¹
Jung Hoon Choi,² Hokoon Park,¹ and Yong Sup Lee^{1,*}

¹Division of Life Sciences, Korea Institute of Science
and Technology, P.O. Box 131, Cheongryang,
Seoul 130-650, Korea

²Department of Chemistry, Hanyang University,
Seoul 133-791, Korea

ABSTRACT

In this research, a new class of pyrrolo[2,1-*a*]isoquinolinone derivative **7** was prepared. C-4 Hydroxylated 5-ethoxylactam **1b** gave 4,5-epoxylactam **2** in high yield instead of isoquinoline derivative **3b** under the *N*-acyliminium ion cyclization condition. The 4,5-epoxylactam **2** was converted to another *N*-acyliminium ion precursor **6** through base-promoted epoxide ring opening, silylation, and thermal Diels–Alder reaction with cyclopentadiene in high yield. Finally, compound **6** was cyclized in the presence of TiCl₄ to provide cyclopentene-fused pyrroloisoquinoline derivative **7**.


*Corresponding author. E-mail: yslee@kist.re.kr



INTRODUCTION

For many researchers, the *N*-acyliminium ion has been used as a reactive intermediate for efficient synthetic method, in particular for carbon–carbon bond formation.^[1] We also recently reported synthetic routes to several heterocyclic systems such as azepinoindole, quinolizidine and indolizidine rings through the *N*-acyliminium ion cyclization strategy.^[2] In our previous synthesis of pyrroloisoquinoline derivatives via *N*-acyliminium ion cyclization of 5-ethoxy or 5-hydroxylactams (for example, **1a**) derived from L-malic acid and L-tartaric acid, the protection of C-4 hydroxyl group was important in getting high yields of cyclized products (Scheme 1).^[3]

In case of refluxing 4-acetoxy-5-hydroxylactam **1a** in formic acid, the cyclized product **3a** was obtained in high yield (74%) whereas the cyclized product **3b** was obtained only in less than 20% yield when 4-hydroxy-5-ethoxylactam **1b** was used in the same reaction condition. We presumed that the low yield of the desired cyclized product was due to the formation of less reactive 4,5-epoxylactam **2** as an intermediate. Herein we wish to report the synthesis and potential utility of **2** by the synthesis of cyclopentene-fused pyrroloisoquinoline derivative **7**.




Scheme 1.



RESULTS AND DISCUSSION

During the investigation of cyclization of **1b**, we found that 4,5-epoxylactam **2** could be obtained in high yield by the treatment of **1b** with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ at room temperature (Scheme 1). The presence of epoxide ring in **2** was proved by the ready conversion to the starting 5-ethoxylactam **1b** upon treatment of 1 N HCl in ethanol. The 4,5-epoxylactam **2** can also be transformed to the cyclized product **3b** in 33% yield when heated at reflux in formic acid. To examine the synthetic utility of **2**, the openings of epoxide ring by several nucleophiles were tried. However, the attempts to open the ring by using ethylmagnesium bromide, allyltrimethylsilane, or trimethylaluminum were unsuccessful. The less reactivity of epoxide ring was unexpected since the epoxide ring-opening reaction of 1-phenoxy-carbonyl-2,3-epoxy-pyrrolidine with allyltrimethylsilane has been known in the literature.^[4]

On the other hand, when **2** was treated with LiHDMS, unsaturated 5-hydroxy-enlactam **4** was obtained in 29% yield. The yield of **4** was improved to 88% yield by using LDA as a base (Scheme 2). Since the enantiomeric purity could not be checked by chiral HPLC or ^1H NMR using chiral shifting agent at this stage, compound **4** was converted to 5-silyloxy-enlactam **5** in 81% yield. The enantiomeric excess of **5** was determined to be 77% by ^1H NMR analysis using the chiral shifting agent $\text{Eu}(\text{hfc})_3$.^[5] The configuration of C-5 was assigned to *S* by comparison of the optical rotation of **5** with that of (*5S*)-1-benzyl-5-(*tert*-butyldimethylsilyloxy)-1,5-dihydro-pyrrol-2-one, which was prepared by Yoda group.^[6] The moderate enantiomeric purity of **5** seems to be due to the slight equilibrium of 5-hydroxy-enlactam **4** to its ring-opened aldehyde-enamide structure during the formation of **4** or the silylation step.



Scheme 2.



The 5-silyloxy-enlactam **5** was used as a dienophile in the thermal Diels–Alder reaction with cyclopentadiene^[7a] to gain a tricyclic lactam **6** in 90% yield. The thermal Diels–Alder reaction of **5** is expected to proceed with a high endoselectivity and diastereoselectivity as was previously reported.^[7] The tricyclic lactam **6** was subjected to the *N*-acyliminium ion cyclization condition to form pentacyclic pyrrolo[2,1-*a*]isoquinolinone ring **7**. Interestingly, the tricyclic lactam **6** did not cyclize efficiently under the influence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ to give the cyclized product **7** only in 10% yield. On the other hand, the stronger Lewis acid, TiCl_4 was an efficient activator^[8] for the cyclization to provide **7** in high yield (77%) and as a single diastereomer resulting from a diastereoselective attack of benzene ring *anti* to the cyclopentene ring during the cyclization. The chemical shifts of each proton and the stereochemistry of angular position in **7** could be fully assigned by using ^1H NMR, in particular ^1H – ^1H COSY techniques.

In conclusion, we have found that C-4 hydroxylated 5-ethoxylactam **1b** gave 4,5-epoxylactam **2** in high yield instead of isoquinoline ring under the *N*-acyliminium ion cyclization condition. The 4,5-epoxylactam **2** was converted to another *N*-acyliminium ion precursor **6** through base-promoted epoxide ring opening, silylation, and thermal Diels–Alder reaction with cyclopentadiene in high yield. Finally, compound **6** was cyclized in the presence of TiCl_4 to provide cyclopentene-fused pyrroloisoquinoline derivative **7**. Although, we have shown one example on the utility of 4,5-epoxylactam by synthesizing cyclopentene-fused pyrroloisoquinoline derivative and the enantiomeric excess of 5-silyloxy-enlactam **5** was not high enough, it seems that 4,5-epoxylactam can be useful intermediate in the synthesis of several chiral or racemic form of isoquinoline or pyrrolidine derivatives by chemical transformation. We are now investigating to improve the enantiomeric excess of 5-silyloxy-enlactam **5**.

EXPERIMENTAL

Melting points were determined with a Thomas-Hoover capillary apparatus and uncorrected. IR spectra were obtained on a Perkin Elmer 16F PC FT-IR spectrometer. The NMR spectra were recorded on Varian Gemini 300 FT or Bruker Advance 300 spectrometers at 300 MHz (for ^1H NMR) and 75 MHz (for ^{13}C NMR). The chemical shifts are reported in ppm downfield relative to tetramethylsilane. Mass spectra were determined with a HP 590 GC/MS 5972 MSD spectrometer and high resolution mass spectra were recorded on a Jeol JMS-AX 505WA mass spectrometer by chemical ionization method (CI) using methane as a carrier gas. Optical rotations were measured on an AUTOPOL III automatic



PYRROLOISOQUINOLINONE DERIVATIVE

2503

polarimeter and all concentrations are given in g/mL. All starting materials were obtained from commercial supplies, and used without further purification. Analytical thin layer chromatography was carried out on pre-coated silica gel (Merck Kiesegel 60 F₂₅₄ layer thickness 0.25 mm). Flash column chromatography was carried out using Kiesegel 60 (230 ~ 400 mesh, Merck).

(1*S*,5*S*)-2-Phenethyl-6-oxa-2-aza-bicyclo[3,1,0]hexan-3-one (2): To a solution of **1b**^[3b] (1.65 g, 6.62 mmol) in CH₂Cl₂ was added dropwise BF₃·Et₂O at -78°C for 10 min under argon atmosphere. After 2 h, the mixture was allowed to warm to r.t. and further stirred for 30 min. The mixture was poured into ice-water containing Na₂CO₃ and extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, concentrated, and purified by flash column chromatography (EtOAc/hexane=2:1) to afford **3** (1.20 g, 89%) as a white solid. *R*_f=0.34 (EtOAc/hexane=2:1) M.p. 112–114°C; MS *m/z*: 203(M⁺); HRMS (CI) Calcd. for C₁₂H₁₄NO₂ (M+H)⁺: *m/z* 204.1025. Found: 204.1020; [α]_D²⁰ +52.6° (*c* 1.48, CHCl₃); IR (KBr, cm⁻¹) 2930, 1704, 1448, 1382, 1284, 1242, 1072, 700; ¹H NMR (CDCl₃) δ 7.28–7.18 (5H, m, phenyl), 4.48 (1H, d, *J*=5.3 Hz, H-5), 4.10–3.98 (1H, m, H-4), 3.71 (1H, m, PhCH₂CH₂-), 3.42 (1H, m, PhCH₂CH₂-), 2.96–2.78 (2H, m, PhCH₂CH₂-), 2.71 (1H, dd, *J*=17.6, 8.3 Hz, H-3), 2.55 (1H, dd, *J*=17.6, 4.9 Hz, H-3'); ¹³C NMR (CDCl₃) δ 171.8, 138.6, 128.7, 128.6, 126.6, 84.3, 66.4, 42.5, 36.0, 34.1.

(5*S*)-5-Hydroxy-1-phenethyl-1,5-dihydropyrrol-2-one (4): To a stirred solution of freshly distilled diisopropylamine (0.26 mL, 1.86 mmol), in THF (10 mL) was added a solution of *n*-butyllithium (0.69 mL, 2.05 mmol, 2.5 M solution in hexane) -78°C under argon atmosphere. The solution of LDA was slowly warmed to 0°C and stirred for 10 min and cooled again to -78°C. To the LDA solution was added dropwise a solution of **2** (315 mg, 1.55 mmol) in THF (10 mL) for 20 min. The reaction mixture was stirred at the same temperature for 30 min and quenched by addition of sat. NH₄Cl. The solution was dispersed into excess CH₂Cl₂ and dried over MgSO₄. The solution was concentrated and the resulting brownish solid was recrystallized from EtOAc/hexane to give **4** (229 mg) as a white solid. The mother liquor was concentrated and purified by flash column chromatography (EtOAc/hexane=2:1) to give 49 mg of **4** additionally. Yield=88%. *R*_f=0.33 (EtOAc/hexane=2/1). M.p. 102–104°C; MS *m/z*: 203 (M⁺); HRMS (CI) Calcd. for C₁₂H₁₄NO₂ (M+H)⁺: *m/z* 204.1025. Found: 204.1030; [α]_D²⁰ +37.8° (*c* 1.08, CHCl₃); IR (KBr, cm⁻¹) 3158, 2832, 1662, 1590, 1428, 1312, 1120, 1090, 694; ¹H NMR (CDCl₃) δ 7.30–7.17 (5H, m, phenyl), 6.85 (1H, d, *J*=6.0 Hz, H-4), 6.05 (1H, d, *J*=6.0 Hz, H-3), 5.12 (1H, br d, *J*=5.7 Hz, H-5), 3.75 (1H, m, PhCH₂CH₂-), 3.51 (1H, m, PhCH₂CH₂-), 2.90 (2H, t, *J*=7.1 Hz, PhCH₂CH₂-); ¹³C NMR (CDCl₃) δ 170.1, 146.4, 139.2, 129.1, 129.0, 128.6, 126.3, 84.2, 41.1, 31.0.



(5*S*)-5-(*tert*-Butyldimethylsilyloxy)-1-phenethyl-1,5-dihydropyrrol-2-one (5): To a stirred solution of **4** (915 mg, 4.5 mmol) in CH₂Cl₂ (20 mL) was added portionwise TBDMSCl (882 mg, 5.9 mmol) and imidazole (460 mg, 6.8 mmol) at r.t. and stirred for 1 h. The mixture was diluted with CH₂Cl₂ and washed with water. The organic layer was dried over MgSO₄, concentrated, and purified by flash column chromatography (EtOAc/hexane = 1 : 5) to give **5** (1.15 g, 81%) as a white solid. *R*_f = 0.23 (EtOAc/hexane = 1/5). M.p. 96–98°C; MS *m/z*: 317(M⁺); HRMS (CI) Calcd. for C₁₈H₂₈NO₂Si (M+H)⁺: *m/z* 318.1889. Found: 318.1881; [α]_D²⁰ +41.9° (*c* 1.40, CHCl₃); IR (KBr, cm⁻¹) 2932, 1690, 1444, 1422, 1362, 1252, 1082, 862; ¹H NMR (CDCl₃) δ 7.24–7.11 (5H, m, phenyl), 6.69 (1H, dd, *J* = 6.0, 1.2 Hz, H-4), 6.06 (1H, d, *J* = 6.0 Hz, H-3), 5.17 (1H, s, H-5), 3.75 (1H, m, PhCH₂CH₂–), 3.26 (1H, m, PhCH₂CH₂–), 2.79 (2H, m, PhCH₂CH₂–), 0.83 (9H, s, –Si(C(CH₃)₃), 0.04 (3H, s, SiCH₃), 0.00 (3H, s, SiCH₃); ¹³C NMR (CDCl₃) δ 169.5, 145.8, 139.4, 129.2, 129.0, 128.9, 126.9, 84.2, 41.1, 35.2, 26.0, 8.4, –3.8, –3.9.

(1*S*,2*S*,5*S*,6*R*,7*R*)-5-(*tert*-Butyldimethylsilyloxy)-4-phenethyl-4-aza-tricyclo [5,2,1,0^{2,6}]dec-8-en-3-one (6): To a dried 10 mL, round-bottom-flask was added **5** (779 mg, 2.45 mmol) and fresh distilled cyclopentadiene (0.6 mL, 7.36 mmol) in dry toluene (20 mL). The reaction solution was heated at reflux for 18 h. After cooling to r.t., the mixture was concentrated under reduced pressure and purified by flash column chromatography (EtOAc/hexane = 1 : 5) to give **6** (842 mg, 90%) as a white solid. *R*_f = 0.26 (EtOAc/hexane = 1 : 5) M.p. 148–150°C; MS *m/z*: 383 (M⁺); HRMS (CI) Calcd. for C₂₃H₃₄NO₂Si (M+H)⁺: *m/z* 384.2359. Found: 384.2368; [α]_D²⁰ – 3.2° (*c* 0.43, CHCl₃); IR (KBr, cm⁻¹) 2956, 1674, 1454, 1388, 1252, 1054, 840; ¹H NMR (CDCl₃) δ 7.16–7.02 (5H, m, phenyl), 5.86 (1H, dd, *J* = 5.6, 2.8 Hz, H-7 or H-8), 5.69 (1H, dd, *J* = 5.6, 2.8 Hz, H-7 or H-8), 4.38 (1H, s, H-5), 3.49 (1H, m, PhCH₂CH–), 3.47–2.89 (5H, m, PhCH₂CH–, H-2, H-6 and H-9), 2.56 (2H, m, PhCH₂CH₂–), 2.42 (1H, m, H-1), 1.39 (1H, d, *J* = 8.4 Hz, H-10), 2.21 (1H, d, *J* = 8.4 Hz, H-10'), 0.78 (9H, s, –Si(C(CH₃)₃), 0.00 (3H, s, SiCH₃), –0.01 (3H, s, SiCH₃); ¹³C NMR (CDCl₃) δ 175.2, 139.2, 136.9, 133.5, 129.1, 128.8, 126.7, 85.6, 51.7, 49.8, 48.3, 45.2, 44.8, 41.2, 34.2, 26.1, 18.3, –3.8, –4.3.

(8*aS*,9*S*,12*R*,12*aR*,12*bR*)-5,8*a*,9,12,12*a*,12*b*-Hexahydro-6*H*-9,12-methano-indeno[1,2-*a*]isoquinolin-8-one (7): To a solution of **6** (295 mg, 0.77 mmol) in CH₂Cl₂ (10 mL) was added dropwise a solution of TiCl₄ (2.31 mL, 2.31 mmol, 1 M solution in CH₂Cl₂) at –78°C for 10 min under argon atmosphere. After stirring for 2 h at the same temperature, the mixture was warmed to r.t. After 30 min, the mixture was poured into ice-water containing Na₂CO₃ and extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, concentrated, and purified by flash column chromatography (EtOAc/hexane = 1 : 5)



PYRROLOISOQUINOLINONE DERIVATIVE

2505

to afford **7** (149 mg, 77%) as a white solid. R_f = 0.21 (EtOAc/hexane = 1 : 5). M.p. 96–98°C; MS m/z : 251 (M^+); HRMS (CI) Calcd for $C_{17}H_{18}NO$ ($M+H$) $^+$: m/z 252.1388. Found: 252.1394; $[\alpha]_D^{20} + 102.4^\circ$ (c 0.81, $CHCl_3$); IR (KBr, cm^{-1}) 3454, 2926, 1680, 1458, 1300, 1250, 1044, 758; 1H NMR ($CDCl_3$) δ 7.29–7.06 (4H, m, phenyl), 6.33 (1H, m, H-11), 6.26 (1H, m, H-10), 4.23 (1H, m, $PhCH_2CH-$), 4.11 (1H, d, J = 2.9 Hz, H-12b), 3.32–3.29 (2H, m, H-9 and H-12), 3.12 (1H, m, $PhCH_2CH_2-$), 2.98 (1H, m, H-8a), 2.66 (2H, m, $PhCH_2CH_2-$), 2.64 (1H, m, $PhCH_2CH_2-$), 1.69 (1H, d, J = 8.5 Hz, H-13), 1.47 (1H, d, J = 8.5 Hz, H-13'); ^{13}C NMR ($CDCl_3$) δ 173.5, 138.9, 137.3, 134.7, 134.0, 129.5, 127.1, 127.1, 125.2, 60.1, 51.8, 51.6, 46.9, 46.2, 44.9, 37.6, 28.6.

REFERENCES

1. For the review, see (a) Speckamp, W.N.; Moolenaar, M.J. *Tetrahedron* **2000**, *56*, 3817; (b) Speckamp, W.N. In *Comprehensive Organic Synthesis*; Trost, B.M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 2, 1047–1082.
2. (a) Lee, Y.S.; Min, B.J.; Park, Y.K.; Lee, J.Y.; Lee, S.J.; Park, H. *Tetrahedron Lett.* **1999**, *40*, 5569; (b) Lee, Y.S.; Cho, D.J.; Kim, S.N.; Choi, J.H.; Park, H. *J. Org. Chem.* **1999**, *64*, 9727; (c) Lee, Y.S.; Lee, J.Y.; Kim, D.W.; Park, H. *Tetrahedron* **1999**, *55*, 4631.
3. (a) Lee, Y.S.; Kang, D.W.; Lee, S.J.; Park, H. *J. Org. Chem.* **1995**, *60*, 7149; (b) Lee, Y.S.; Kang, D.W.; Lee, S.J.; Park, H. *Synth. Commun.* **1995**, *25*, 1947.
4. Laurence, E.B.; Gross, E.K.M.; Jurka, J. *Tetrahedron Lett.* **1996**, *37*, 3255.
5. Tris[3-[(heptafluoropropyl)hydroxymethylene]-*d*-camphorato]europium(III) ($Eu(hfc)_3$) was purchased from Aldrich company. For comparison, racemic form of **5** was prepared from (\pm)-malic acid by the same procedure for the synthesis of (*S*)-**5**. Enantiomeric excess was determined by integration of H-3 peaks at 6.87 and 6.76 ppm from 1H NMR spectrum of (*S*)-**5** in the presence of $Eu(hfc)_3$.
6. Yoda, H.; Kitayama, H.; Katagiri, T.; Takable, K. *Tetrahedron* **1992**, *48*, 3313.
7. (a) Speckamp, W.N.; Hiemstra, H.; Koot, W.-J. *J. Org. Chem.* **1992**, *57*, 1059; (b) Feringa, B.L.; de Jong, J.C.; Bolhuis, F. *Tetrahedron: Asymmetry* **1991**, *2*, 1247.
8. Marson, C.M.; Brooks, P.B. *Tetrahedron* **1998**, *54*, 9613.

Received in the Japan June 8, 2001



MARCEL DEKKER, INC. • 270 MADISON AVENUE • NEW YORK, NY 10016

©2002 Marcel Dekker, Inc. All rights reserved. This material may not be used or reproduced in any form without the express written permission of Marcel Dekker, Inc.